What explains the diffusion of treatments for mental illness?

American Journal of Psychiatry

Volumn 165, Issue 11, 2008, Pages 1385-1392

  Drake, Robert ^a   Skinner, Jonathan ^b   Goldman, Howard H ^b  

^a DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ATTITUDE; DECISION MAKING; DEPRESSION; EVIDENCE BASED MEDICINE; FUNDING; HEALTH CARE AVAILABILITY; HEALTH CARE DISTRIBUTION; HUMAN; INFORMATION DISSEMINATION; MARKETING; MEDICAL INFORMATION; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; NOTE; PRIORITY JOURNAL; PROFIT; PSYCHOTHERAPY; PUBLIC HEALTH SERVICE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DIFFUSION OF INNOVATION; DRUG COSTS; EVIDENCE-BASED MEDICINE; FORECASTING; HEALTH POLICY; HUMANS; INSURANCE COVERAGE; MARKETING OF HEALTH SERVICES; MEDICAID; MENTAL DISORDERS; PREJUDICE; QUALITY ASSURANCE, HEALTH CARE; RESEARCH; SCHIZOPHRENIA; UNITED STATES;

EID: 55749109049     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.08030334     Document Type: Note

References (63)

1. Newhouse JP: Medical care costs: how much welfare loss? J Econ Perspect 1992; 6:3-21
2. Berwick DM: Disseminating innovations in health care. JAMA 2003; 289:1969-1975
3. Rogers EM: Diffusion of Innovations, 5th ed. New York, Free Press, 2003
4. Wennberg JE: Understanding variations in healthcare delivery. N Engl J Med 1999; 340:52-53
5. New Freedom Commission on Mental Health: Achieving the Promise: Transforming Mental Health Care in America: Final Report. U.S. Department of Health and Human Services Publication SMA-03-3832. Rockville, Md, DHHS, 2003
6. U.S. Department of Health and Human Services: Mental Health: A Report of the Surgeon General. Rockville, Md, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999
7. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC: Twelve-month use of mental health services in the United States. Arch Gen Psychiatry 2005; 62:629-640
8. Frank R, Glied S: Better But Not Well. Baltimore, Md, Johns Hopkins University Press, 2006
9. Lehman AF, Steinwachs DM, Co-investigators of the PORT Project: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Studies. Schizophr Bull 1998; 24:11-20
10. Griliches Z: Hybrid corn: an exploration in the economics of technological change. Econometrica 1957; 25:501-522
11. Havens AE, Rogers E: Adoption of hybrid corn: profitability, and the interaction effect. Rural Sociol 1961; 26:409-414
12. Greenhalgh T, Robert G, MacFarlane F, Bate P, Kyriakidou O: Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q 2004; 82:581-629
13. Tolbert PS, Zucker LG: Institutional sources of change in the formal structure of organizations: the diffusion of civil service reform 1880-1935. Admin Sci Quarterly 1983; 28:22-39
14. Coleman JS, Katz E, Menzel H: Medical Innovation: A Diffusion Study. New York, Bobbs-Merrill, 1966
15. Essock SM, Goldman HH, Van Tosh L, Anthony WA, Appell CR, Bond GR, Dixon L, Dunakin L, Ganju V, Gorman P, Ralph RO, Rapp CA, Teague GB, Drake RE: Evidence-based practice: setting the context and responding to concerns. Psychiatr Clin North Am 2003; 26:919-938
16. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335-371
17. Jencks SF, Huff ED, Cuerdon T: Change in the quality of care delivered to Medicare beneficiaries 1998-1999 to 2000-2001. JAMA 2003; 289:305-312
18. Bradley EH, Holmboe ES, Mattera JA, Roumanis SA, Radford MJ, Krumholz HM: A qualitative study of increasing β-blocker use after myocardial infarction: why do some hospitals succeed? JAMA 2001; 285:2604-2611
19. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SM, Oslin DW, Kampman KM, Dackis CA: The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharm 2006; 26:610-625
20. Ducharme LJ, Knudsen HK, Roman PM: Trends in the adoption of medications for alcohol dependence. J Clin Psychopharm 2006; 26:S13-S19
21. Grant BF: Prevalence and correlates of drug use and DSM-IV drug dependence in the United States: results of the national longitudinal alcohol epidemiologic survey. J Subst Abuse Treat 1996; 8:195-210
22. Substance Abuse and Mental Health Services Administration: National Household Survey on Drug Abuse. http://www.oas.xamsa.gov/nhsda.htm
23. Mark TL, Kranzler HR, Poole VH, Hagen CA, McLeod C, Crosse S: Barriers to the use of medications to treat alcoholism. Am J Addict 2003; 12:281-294
24. Henggeler SW, Schoenwald SK, Borduin CM, Rowland MD, Cunningham PB: Multisystemic Treatment of Antisocial Behavior in Children and Adolescents. New York, Guilford, 1998
25. Schoenwald SK: Toward evidence-based transport of evidence-based treatments: MST as an example. J Child Adolesc Subst Abuse Treat (in press)
26. Henggeler SW, Melton GB, Smith LA: Family preservation using multisystemic therapy: an effective alternative to incarcerating serious juvenile offenders. J Consult Clin Psychol 1992; 60:953-961
27. Henggeler SW, Melton GB, Smith LA, Schoenwald SK, Hanley J: Family preservation using multisystemic therapy: long-term follow-up to a clinical trial with serious juvenile offenders. J Child Family Studies 1993; 2:283-293
28. Unützer J, Katon W, Williams JW, Callahan CM, Harpole L, Hunkeler EM, Hoffing M, Arean P, Hegel MT, Schoenbaum M, Oishi SM, Langston CA: Improving primary care for depression in late life: the design of a multicenter randomized trial. Med Care 2001; 39:785-799
29. Unützer J, Katon W, Callahan CM, Williams JW, Hunkeler E, Harpole L, Hoffing M, Della Penna RD, Noel PH, Lin EH, Arean PA, Hegel MT, Tang L, Belin TR, Oishi S, Langston: Collaborative care management of late-life depression in the primary care setting. JAMA 2002; 288:2836-2845
30. Katon W, Robinson P, VonKorff M, Lin E, Bush T, Ludman E, Simon G, Walker CA: A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 2005; 53:924-932
31. Grypma L, Haverkamp R, Little S, Unutzer J: Taking an evidence-based model of depression care from research to practice: making lemonade out of depression. Gen Hosp Psychiatry 2006; 28:101-107
32. Unützer J, Powers D, Katon W, Langston C: From establishing an evidence-based practice to implementation in real-world settings: IMPACT as a case study. Psychiatr Clin North Am 2005; 28:1079-1092
33. Scheffler RM, Adams N: Millionaires and mental health: Proposition 63 in California. Health Affairs 2005; W5:212-224
34. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N, Steinwachs DM: The schizophrenia patient outcomes research team (PORT): updated treatment recommendation 2003. Schizophr Bull 2004; 30:193-217
35. Lehman AF, Steinwachs DM, and the Co-Investigators of the PORT Project: Translating research into practice: the schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24:1-10
36. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-564
37. Buono D: IMS study finds decline in prescription drug market growth. Drug Store News. April 21, 2008. Findarticles.com, 13 Aug, 2008. http://findarticles.com/articles/mi_m3374/P/is_5_30ai_n25407255
38. Owens DC: What CATIE did: some thoughts on implications deep and wide. Psychiatr Serv 2008; 59:530-533
39. Rosenheck RA, Leslie DL, Doshi JA: Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Psychiatr Serv 2008; 59:515-520
40. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of the effect on quality of life of second-vs-first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63:1079-1087
41. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe SE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2006; 353:1209-1223
42. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell NR, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Tevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349
43. McEvoy JP, Meyer J, Goff D, Nasrallah H, Davis SM, Sullivan L, Meltzer HY, Stroup TS, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: results from CATIE and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19-32
44. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM: Use of ezetimibe in the United States and Canada. N Engl J Med 2008; 358:1819-1828
45. Wennberg D (ed): Dartmouth Atlas of Cardiovascular Healthcare. Dartmouth Medical School and the American Hospital Association, 2000
46. Wang PS, Demier O, Kessler RC: Adequacy of treatment for serious mental illness in the United States. Am J Public Health 2002; 92:92-98
47. Semke J, Perdue S: Regional patterns of service for individuals with severe mental illness. Admin Policy Ment Health Serv Res 1998; 25:541-547
48. Becker T, Vázquez-Barquero JL: The European perspective of psychiatric reform. Acta Psychiatrica Scandinavica 2001; 104:8-14
49. Kramer TL, Daniels AS, Zieman GL, Williams C, Dewan NA: Psychiatric practice variations in the diagnosis and treatment of major depression. Psychiatr Serv 2000; 51:336-340
50. Ashton C: Geographic variations in utilization rates in Veterans Affairs Hospitals and clinics. N Engl J Med 1999; 340:32-39
51. Wright D, Sathe N, Spagnola K: State estimates of substance use from the 2004-2005 National Surveys on Drug Use and Health: DHHS Publication SMA 07-4235, NSDUH Series H-31. Rockville, Md, Substance Abuse and Mental Health Services Administration, Office of Applied Sciences, 2007
52. Baer JS, Ball SA, Campbell BK, Miele GM, Schoener EP, Tracy K: Training and fidelity monitoring of behavioral interventions in multi-site addictions research. Drug Alcohol Depend 2007; 87:107-118
53. Dietrich AJ, Oxman TE, Williams JW, Schulberg HC, Bruce ML, Lee PW, Barry S, Raue PJ, Lefever JJ, Heo M, Rost K, Kroenkie K, Gerrity M, Nutting PA: Re-engineering systems for the treatment of depression in primary care: cluster randomized controlled trial. Br Med J 2004; 329:602-605
54. Dopson S, Fitzgerald L, Ferlie E, Gabby J, Locock L: No magic targets: changing clinical practice to become more evidence based. Manage Rev 2002; 37:35-47
55. Gotham HJ: Advancing the implementation of evidence-based practices into clinical practice: How do we get there from here? Prof Psycho Res Pract 2006; 37:606-613
56. Hermann RC: Improving Mental Healthcare: A Guide to Measurement-Based Quality Improvement. Washington, DC, American Psychiatric Press, 2005
57. McHugo GM, Drake RE, Whitley R, Bond GR, Campbell K, Rapp CA, Goldman HH, Lutz W, Finnerty M: Fidelity outcomes in the National Implementing Evidence-Based Practices Project. Psychiatr Serv 2007; 58:1279-1284
58. Miller WR, Sorensen JL, Selzer JA, Brigham GS: Disseminating evidence-based practices in substance abuse treatment: a review with suggestions. J Subst Abuse Treat 2006; 31:25-39
59. Shojania KG, Grimshaw JM: Evidence-based quality improvement: the state of the science. Health Affairs 2005; 24:138-150
60. Skinner J, Staiger D: Technological diffusion from hybrid corn to beta blockers, in Hard-to-Measure Goods and Services: Essays in Honor of Zvi Griliches. Edited by Berndt E, Hulten CM. Chicago, University of Chicago Press and NBER, 2007
61. Putnam R: Bowling Alone: The Collapse and Revival of American Community. New York, Simon & Schuster, 2000
62. Williams J: Geographic variations in health care utilization: the effects of social capital and self-interest. AARP Working Paper, Washington, DC, 2007
63. Landon BE, Wilson IB, McInnes K, Landrum MB, Hirschhorn L, Marsden PV, Gustafson D, Cleary PD: Effects of a quality improvement collaborative on the outcome of care of patients with HIV infection: the EQHIV study. Ann Intern Med 2004; 140:887-896